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Prevalence of genital chlamydia infection in
urban women of reproductive age, Nairobi, Kenya
Ruchika Kohli1*, Walter P Konya2, Timona Obura2, William Stones2 and Gunturu Revathi1
Abstract
Background: Chlamydia trachomatis is one of the major causes of sexually transmitted infections throughout the
world. Most infections are asymptomatic and remain undetected. Burden of disease in the Kenyan population is not
well characterised. This study was done to define the prevalence of genital Chlamydia infection in a representative
female population.
Findings: A cross-sectional study design was employed. All women attending out-patient clinics (antenatal,
gynaecology, family planning) and accident and emergency departments at two study sites over a five month
period were invited to consent to completion of a questionnaire and vaginal swab collection. A rapid point-of-care
immunoassay based test was performed on the swabs. Women who tested positive for Chlamydia were offered
treatment, together with their partner(s), and advised to come for a follow-up test.
A total of 300 women were tested. The prevalence of genital Chlamydia trachomatis was found to be 6% (95% CI
3.31% – 8.69%). The prevalence was higher in women who represented a higher socioeconomic level, but this
difference was not significant (p=0.061). Use of vaginal swabs was observed to be a more acceptable form of
sample collection.
Conclusion: The prevalence of genital Chlamydia is significant in our female population. There is a justifiable need
to institute opportunistic screening programs to reduce the burden of this disease. Rapid and low cost
point-of-care testing as a potential component of sexually transmitted infection (STI) screening can be utilised.
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Findings
Introduction
In Kenya like in many African countries, the syndromic
approach is used in the treatment of genital infections.
However, this may not be entirely effective for Chlamydia
trachomatis due to the asymptomatic nature of this infec-
tion in many women and the possibility of missing
selected infections. Failure to detect infection can have se-
vere consequences including ectopic pregnancy, infertility
and pelvic inflammatory disease caused by fibrosis and
scarring due to the repair of tissue damaged by Chlamydia
induced inflammation [1].
With newer diagnostic methodologies available, testing
is simple and less technically demanding. Rapid point-
of-care diagnostic tests are particularly important in
developing countries, where access to laboratories may
be limited and patients are often unable or unwilling to
return for test results or treatment [2,3]. Non invasive
specimen types are preferable because they overcome
some of the barriers associated with the treatment of
sexually transmitted infections by being more accessible
to the population at risk [4-6]. In addition, it provides
the opportunity to diagnose, treat and counsel during
the same visit. The Chlamydia Rapid TestW, which was
used as the diagnostic tool in this study, is an immuno-
assay based test that detects chlamydial lipopolysacchar-
ide (LPS). This test uses vaginal swabs as the specimen
type and provides a same day result. Performance evalu-
ation indicates that this point of care test can be used
for diagnosis of chlamydial infection because of its good
sensitivity (83.5%), specificity (98.9%), negative and posi-
tive predictive values (98.6% and 86.7% respectively) [2].
Treatment of infection is also effective, inexpensive
and readily available and community screening programs
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have been instituted in some countries to control the
progression of disease, prevent the transmission to
current or new partner(s), and allow contact tracing,
testing and treatment [7].
Study design and methodology
The aim of this study was to assess the public health
burden of genital Chlamydia infection in sexually active
females of reproductive age. A prospective cross-
sectional study conducted at two hospital sites within
Nairobi, Kenya was conducted. The two sites chosen
represented a population with different socio-economic
status.
Adult women aged, 18–45 years, who were currently
sexually active and were attending the outpatient clinics
and accident and emergency departments at the two
study sites during the study period were recruited (Figure 1).
Exclusion criteria included women who declined to give
informed consent, those who were not accessible for
follow-up after testing and those who were on chronic
antibiotic treatment. A sample size of 300 was predeter-
mined and calculated using prevalence rates from previous
studies conducted in Kenya. Chlamydia testing was con-
ducted on site, either by the principal investigator or a
qualified nurse, deemed competent to run the test. The test
had an in-built procedural control and known positive and
negative control samples (supplied with each kit) were run
concurrently with test samples. SPSS (version 15.0) and
Microsoft Excel were used for data analysis.
Research and Ethics committees of both participating
hospitals (Aga Khan University Research Ethics Commit-
tee and St. Mary’s Mission Hospital, Nairobi, Kenya)
approved the study.
Results
Patients were recruited over a period of five months, July
to November, 2010. 150 women from each study site
(a total 300 women) fulfilled the eligibility criteria (see
Figure 1). Women were recruited equally from the dif-
ferent clinics sampled.
Study Site Two
(n = 150)
Study Site One
(n = 150)
Written informed consent form and 
questionnaire to obtain 
demographic and social history 
Vaginal Swab
Self Collection
(n = 105)
Collection by Health-Care 
Professional
(n = 195)
Chlamydia Rapid Test®
(n = 300)
Negative
(n = 282) Positive
(n = 18)
No further follow up required
Treatment Patient and Partner(s) 
with 1g Azithromycin® as a STAT 
dose
(n = 17)
Follow up patient for a repeat test 
after 3-5 weeks
(n = 13)
Eligibility Criteria
- Sexually active females;
- 18-45 years old
Patient 
refused 
treatment
(n = 1)
Did not 
return for 
follow -up
(n = 4)
Excluded (n=13)
- Antibiotics (1)
- Menses (4)
- Refusal to give
consent (9)
Excluded (n=5)
- Menses (2)
- Refusal to give 
consent (3)
Figure 1 Schematic of the recruitment and testing algorithm.
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Table 1 below highlights the social and demographic
differences between the two study populations.
The prevalence of infection in the study population
was 6% (18/300) (95% Cl 3.31% to 8.69%) [8]. The ma-
jority of the women who tested positive were from site
one, 8.67% (13/150) (95% CI 4.17% to 13.17%), while
3.33% (5/150) (95% CI 0.46% to 6.2%) were from site two.
Most participants were aged between 30–35 years,
26.3% (79/300). Frequency of genital Chlamydia was
highest amongst women aged 25–30 years, 2% (6/300),
followed by females aged 35–40 years and 40–45 years,
1.7% (5/300). Confidence intervals comparing partici-
pants’ age group and frequency of infection showed a
significant higher risk of acquiring infection in patients
aged 25–30 years compared to those between 30–35 years
(Table 2).
Patients from site one were generally of a higher socio-
economic standing than those from site two; parameters
used to assess this difference included patient education,
monthly income and rent. More patients, 51% (76/150),
from site one had a graduate education compared to
3.3% (5/150) from site two. Only 14% (21/150) of
patients from site one had no income compared with
35% (53/150) from site two.
55.6% (10/18) of women with a positive Chlamydia test
result were older than 20 years old at first sexual en-
counter. No significant difference was present when
odds ratios were calculated to determine if age at sexual
onset (p=0.753), duration of sexual activity (p=0.57) and
number of lifetime partners (p=0.928) predisposed to
genital Chlamydia infection (Table 1).
77.7% (233/300) of women found the vaginal swab
more acceptable than an endocervical swab. Of these,
18% (42/233) preferred collecting the sample themselves.
Patients who tested positive were counselled about the
infection and offered treatment for themselves and their
partner(s). One patient refused treatment. Four patients
(22.2%) did not return for follow-up testing. Of the thir-
teen patients who returned for a follow-up testing one
patient re-tested as positive. However, on repeat testing
Table 1 Summary of social and demographic characteristics of patient population at the two study sites
Patient characteristic Site one Site two
Number of participants 150 150
Marital status Married Married
(95/150, 63.3%) (110/150, 73.3%)
Contraceptive use No method No method
(29%, 43/150) (52%, 78/150)
Length of sexual activity
<15 years 78.7%, 118/150 72.7%, 109/150
>15 years 21.3%, 32/150 27.3%, 41/150
Greater than 2 lifetime Partners 42.7%, 64/150 16.7%, 25/150
Asymptomatic patients with Chlamydia infection 76.9%, 10/13 80%, 4/5
Acceptability of vaginal swab compared to
endocervical swab
70.1%, 106/150 84.7%, 127/150
Patient knowledge about Chlamydia infection Did not know what Chlamydia
trachomatis was
Majority reported it as a sexually transmitted
infection
(117/150, 78%) (90/150, 60%)
Table 2 Confidence intervals comparing age groups of patients and a positive chlamydia test
Age Number of participants Chlamydia test positive Frequency and
confidence
intervals (%)
(n=300) (n=18)
Site one Site two Total Site one Site two Total
<20 years 4 2 6 0 0 0 0 (0–0)
20-25 years 21 27 48 0 0 0 0 (0–0)
25-30 years 39 38 77 4 2 6 33.3 (22.2 – 44.4)
30-35 years 40 39 79 2 0 2 11.1 (3.7 – 18.5)
35-40 years 26 21 47 3 2 5 27.8 (17.2 – 38.3)
40-45 years 20 23 43 4 1 5 27.8 (17.2 – 38.3)
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one month later the test was negative without a second
dose of antibiotics.
Discussion
The overall prevalence of 6% is comparable with previ-
ous published reports from Kenya, which showed varied
prevalence rates of between 4.2% and 21% [9-11]. Al-
though the target populations in those studies differed
from ours, it is interesting that the prevalence rates re-
main similar indicating that the burden of disease has
not decreased in recent times suggesting that relevant
intervention strategies are still necessary.
The high prevalence noted among women of greater
socioeconomic standing suggests that presence of infec-
tion in this group has been largely ignored by previous
studies from this region. Our study provides new infor-
mation and highlights the need to institute active oppor-
tunistic screening programs across all socioeconomic
groups.
Few studies from Kenya or Africa have examined the
prevalence of genital Chlamydia with reference to age
unlike in the developed world, where this is the funda-
mental focus. Investigators have found that the preva-
lence of Chlamydia infection is highest in younger
women especially those under the age of 25 years
[12,13]. Although this study was not sufficiently powered
to determine the effects of age on prevalence rate, the
prevalence rate was highest in women aged 25–30 years,
2%, emphasising that even in our population young
women are at higher risk of being infected. Due to eth-
ical concerns, our study population was aged between
18 and 45 years, excluding sexually active teenage girls,
which could imply that we might have missed an age
group with higher burden of infection.
In our study, 50% (150/300) of the women were older
than 20 years of age at the time of first sexual encounter.
Studies differ, revealing the disparities in social and sex-
ual behaviour and cultural backgrounds between differ-
ent countries [13,14]. There was no significant difference
between the age of first sexual encounter and infection
with Chlamydia. The reason for this might be two-fold;
first our study population did not include women
younger than 18 years and second our sample size was
not large enough to detect a difference in the prevalence
of infection with respect to age.
Patients of a higher socioeconomic standing, with a
higher prevalence of genital Chlamydia infection, had
more than two lifetime partners. Our findings reiterate
what other studies have shown and it is postulated that
multiple partnerships may increase the likelihood of
encountering a sexually transmitted pathogen through
the increased probability of choosing a partner with in-
fection, while having new or casual sexual contacts may
be related to increased risk because of a reduced famil-
iarity between partners [14,15].
The majority of patients who tested positive for Chla-
mydia were asymptomatic, highlighting the inadequacy
of using syndromic management in such patients. This
finding reinforces the need to institute screening pro-
grams with the use of low cost and rapid point of care
testing to prevent potential spread of infection in sus-
ceptible populations.
This is the first study in Kenya using a rapid point-of
care diagnostic test with a non invasive vaginal swab as
the specimen type enabling patients to get tested and
treated within one clinic visit. The majority preferred
the non invasive vaginal swab as compared to the con-
ventional endocervical swab for specimen collection.
Rates of contraceptive use were low, possibly due to
most women being married and in a monogamous rela-
tionship. Few women preferred barrier contraceptives
therefore increasing their risk of becoming infected with
genital Chlamydia and indeed with other sexually trans-
mitted infections.
Most women had little or no knowledge about genital
Chlamydia trachomatis as campaigns on sexually trans-
mitted infections in this region tend to focus more on
other infectious agents such as HIV, gonorrhoea and
herpes simplex. The asymptomatic nature of this infec-
tion accentuates the need to educate patients about
associated risk factors and available testing modalities.
Conclusion
Prevalence of genital Chlamydia remains significant in
our population especially in women living in highly
urbanised areas. This new information provides evidence
for the need to implement active opportunistic screening
in young sexually active women in our population in
patients of all socioeconomic groups. Point of care tests
can be employed for infection detection, enabling rapid
screening of large numbers with provision of a same day
result and treatment if required.
There is a considerable gap in current awareness about
genital Chlamydia and an urgent need to prioritise pa-
tient and community education, so that young sexually
active females are aware of the inherent risk factors that
can predispose them to infections.
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